Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heidi Shea

Endocrinology, Diabetes & Metabolism Plano, TX Medical Doctor

NPI 1578517926 CMS profile 252357

1820 Preston Park Blvd, Suite 1850, Plano, TX 75093

Open in the dashboard

General payments

$186,030

1,231 records reported · program years 2019–2025

Research payments

$55,774

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,059,422 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Heidi Shea of Plano, TX is reported in the CMS Open Payments database as having received $186,030 across 1,231 general payments and $55,774 in research payments paid to them. Separately, studies naming them as principal investigator received $1,059,422 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55,321 208
2024 General $24,636 172
2023 General $16,872 169
2022 General $32,104 195
2022 Research $55,774 2
2021 General $20,488 146
2020 General $11,885 151
2019 General $24,725 190

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heidi Shea
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Heidi Shea were reported at $55,321. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Heidi Shea Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $24,725 $494 $123–$2,253 $163
2020 $11,885 $335 $85–$1,841 $114
2021 $20,488 $398 $88–$1,981 $132
2022 $32,104 $364 $88–$1,568 $149
2023 $16,872 $420 $113–$1,614 $160
2024 $24,636 $440 $121–$1,646 $164
2025 $55,321 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $83,210 241 payments
  2. Neurocrine Biosciences, Inc. $25,077 32 payments
  3. Rhythm Pharmaceuticals, Inc. $22,379 24 payments
  4. Ascendis Pharma, Inc. $21,838 38 payments
  5. Soleno Therapeutics, Inc. $7,610 5 payments
  6. Endo Pharmaceuticals Inc. $6,487 7 payments
  7. Tandem Diabetes Care, Inc. $3,568 20 payments
  8. Insulet Corporation $1,212 61 payments
  9. Lilly USA, LLC $1,093 72 payments
  10. Amgen Inc. $1,049 58 payments
  11. Other $12,507 673 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,577 59 payments
  2. Consulting Fee $46,568 17 payments
  3. Food and Beverage $22,051 1,080 payments
  4. Honoraria $18,563 8 payments
  5. Travel and Lodging $8,985 41 payments
  6. Education $287 26 payments
Products named General payments · program years 2019–2025
  1. Norditropin Growth Hormone $28,341 50 payments
  2. Sogroya $27,494 39 payments
  3. SKYTROFA $21,713 33 payments
  4. Imcivree $17,890 16 payments
  5. Norditropin Growth Hormone $17,453 22 payments
  6. CRENESSITY $14,399 21 payments
  7. VYKAT XR $7,610 5 payments
  8. SUPPRELIN $6,487 7 payments
  9. Macrilen $5,100 3 payments
  10. t:slim X2 insulin pump $2,298 9 payments
  11. Other $22,988 1,213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $55,774 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

786

Median for Endocrinology: 1,959

Drug cost

$238,962

Median for Endocrinology: $890,201

Branded share of claims

44.4%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 39 $51,333
Trulicity Dulaglutide Brand 32 $48,394
Mounjaro Tirzepatide Brand 34 $41,462
Jardiance Empagliflozin Brand 27 $41,415
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $22,057
Tresiba Flextouch U-100 Insulin Degludec Brand 13 $8,527
Synthroid Levothyroxine Sodium Brand 86 $8,509
Testosterone Generic 13 $2,799
Humalog Kwikpen U-100 Insulin Lispro Brand 11 $2,159
Ultra-Fine Short Pen Needle Pen Needle, Diabetic Brand 13 $2,138

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$54,282

Medicare's payments for the services billed

Medicare patients

191

Average age 72

Services billed

2,302

148 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Diabetes 45%
Osteoporosis 36%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 21%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sogroya
$14,660 — —
JARDIANCE
$234 27 —
AFREZZA
$206 — —
TZIELD
$136 — —
SYNTHROID
$128 86 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record